Changes in the expression of insulin-like growth factor 1 variants in the postnatal brain development and in neonatal hypoxia-ischaemia
| Autor: | Dariusz C. Górecki, Dorota Makarewicz, Małgorzata Beręsewicz, Steven Vayro, Monika Majewska, Barbara Zabłocka |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Gene isoform
Male medicine.medical_specialty Time Factors medicine.medical_treatment Ischemia Endogeny Biology Neuroprotection Insulin-like growth factor Developmental Neuroscience Internal medicine Cell Line Tumor medicine Animals Protein Isoforms RNA Messenger Insulin-Like Growth Factor I Rats Wistar Hypoxia Brain Neonatal stroke Neurons Brain Cell Differentiation Hypoxia (medical) medicine.disease Rats Endocrinology Animals Newborn Hypoxia-Ischemia Brain Female medicine.symptom Developmental Biology Biomedical sciences |
| Zdroj: | International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. 28(1) |
| ISSN: | 1873-474X |
| Popis: | Insulin-like growth factor-1 (IGF-1) is a multifunctional peptide of which numerous isoforms exist. The predominant form, IGF-1Ea is involved in physiological processes while IGF-1Ec (mechano-growth factor, MGF) is expressed in response to a different set of stimuli. We have identified specific changes in the expression patterns of these IGF-1 variants in brain development in normal rats and following neonatal hypoxia-ischaemia (HI). Both IGF-1Ea and IGF-1Ec are expressed during normal postnatal brain development, albeit with highly specific temporal distributions. In contrast, HI produced increased and prolonged expression of the IGF-1Ec isoform only. Importantly, hypoxia alone stimulated the expression of IGF-1Ec as well. Thus, IGF-1Ec may play a role in HI pathology. Neonatal hypoxia-ischaemia occurs in approximately 1:4000-1:10,000 newborns and causes neurological deficits in approximately 75% of those affected. Unfortunately, no specific treatment is available. IGF-1 is known to have neuroprotective activity and its IGF-1Ec variant appears to be an endogenous protective factor in hypoxia-ischaemia. Therefore, IGF-1Ec could potentially be developed into a therapeutic modality for the attenuation or prevention of neuronal damage in this and related disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text